8-K: Optinose Announces Preliminary Q4 2024 XHANCE Net Revenue of $22.4 Million, Showing 20% Prescription Growth

Optinose reported preliminary unaudited net revenue of $22.4 million for XHANCE in the fourth quarter of 2024, with an estimated 20% sequential prescription growth rate.

Summary

• Optinose announced preliminary unaudited net product revenue for XHANCE of $22.4 million for the fourth quarter of 2024.
• The company estimates a 20% sequential growth rate in XHANCE prescriptions from the third to the fourth quarter of 2024.
• These results are preliminary and have not been audited or reviewed by the company's independent accounting firm.
• The company expects to report full financial results for the fourth quarter of 2024 and provide corporate updates in March.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the in-line revenue and strong prescription growth, but tempered by the preliminary nature of the results and the associated risks.

Positives

• The $22.4 million in preliminary net revenue for XHANCE is in line with prior guidance.
• The estimated 20% sequential growth in XHANCE prescriptions indicates strong market demand.
• The company is focused on commercial execution and continued growth.

Negatives

• The reported results are preliminary and unaudited, and actual results may vary materially.
• The company cautions against placing undue reliance on the preliminary data.

Risks

• The final Q4 2024 financial results may differ materially from the preliminary figures due to financial closing procedures and review adjustments.
• The preliminary prescription growth rate may change upon finalization of third-party data.
• There are risks associated with physician and patient acceptance of XHANCE for its new indication.
• The company's ability to maintain adequate third-party reimbursement for XHANCE is a risk.
• The market opportunities for XHANCE may be smaller than expected.
• The company's ability to efficiently generate XHANCE prescriptions and net revenues is a risk.

Future Outlook

The company anticipates continued growth in XHANCE prescriptions and plans to report full financial results and corporate updates in March.

Management Comments

• CEO Ramy Mahmoud stated that the preliminary Q4 net product revenue of $22.4 million is in line with prior guidance.
• He also noted the sustained growth in XHANCE prescriptions through the fourth quarter of 2024.
• The company is focused on commercial execution and continued growth in the year ahead.

Industry Context

This announcement reflects Optinose's progress in the specialty pharmaceutical market, particularly in the ENT and allergy space, and indicates the company's ability to generate revenue from its key product, XHANCE.

Comparison to Industry Standards

• It is difficult to compare this result to industry standards without knowing the specific growth rates of similar products in the ENT and allergy space.
• However, a 20% sequential prescription growth rate is generally considered strong for a pharmaceutical product in this sector.
• Companies like Sanofi and Regeneron, which have products in the allergy and respiratory space, could be considered comparators, but their product portfolios and market positions are different.

Stakeholder Impact

• Shareholders will be interested in the final Q4 2024 results and the company's future growth prospects.
• Employees will be impacted by the company's performance and future strategies.
• Patients will benefit from the continued availability of XHANCE.

Next Steps

• The company will finalize its Q4 2024 financial results.
• The company will report full financial results and corporate updates in March.

Key Dates

Keywords

XHANCE, Optinose, Net Revenue, Prescription Growth, Pharmaceutical, ENT, Allergy, Q4 2024, Financial Results